With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

Learn how an unlikely discovery in a venomous lizard led to one of today’s most influential drugs and why future ...

A new national study has placed a spotlight on weight and health across the United States, and the numbers are stark.

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...

Three new studies reveal surprising insights on GLP-1 weight loss drugs, opioid treatment in pregnancy, and the real science ...

Although the window for Rhythm Pharmaceuticals’ Imcivree to break out of the genetic obesity realm is quickly approaching with an upcoming FDA decision, a few other potential areas of expansio | The ...

Novo Nordisk remains a 'Hold' as its valuation reflects justified concerns over eroding GLP-1 market share and regulatory ...

Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real ...

The writers for this edition's Point and Counterpoint columns are addressing the question, "Should the U.S. expand access to ...

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification ...

Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific ...